Physician profile
Benjamin Raab
NPI 1992753925
$2,742.78
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.95 · 2022: $887 · 2023: $1,074 · 2024: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,698.66 |
| Education | $133.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $961.97 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $331.11 | 2022-2024 | Ilumya |
| Amgen INC. | $297.48 | 2021-2024 | Otezla |
| Genzyme Corporation | $292.63 | 2022-2024 | |
| Lilly USA, LLC | $162.40 | 2022-2023 | Taltz, Olumiant |
| Leo Pharma INC. | $131.01 | 2022-2024 | Adbry |
| Biofrontera INC. | $100.46 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| E.R. Squibb & Sons, L.L.C. | $80.57 | 2022-2023 | Sotyktu |
| Dermavant Sciences, INC. | $79.67 | 2023 | Vtama |
| Organogenesis INC. | $66.04 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.99 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $31.27 | 2024 | Aklief |
| Pfizer INC. | $30.53 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $29.91 | 2023 | |
| Arcutis Biotherapeutics, INC. | $22.33 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $19.98 | 2024 | Tremfya |
| Journey Medical Corporation | $16.71 | 2024 | |
| Verrica Pharmaceuticals INC. | $16.24 | 2023 | Ycanth |
| Incyte Corporation | $13.48 | 2023 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Raab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.